Small Cap Gainers: SAVA, PAVM, VERI
3:48 pm Thursday, September 23rd, 2021
Cassava Sciences Inc (NASDAQ: SAVA) gains to its highest levels since August, continuing to improve off of recent four-month lows. Co yesterday morning reported top-line data from an interim analysis of its study evaluating simufilam in Alzheimer’s disease.
PAVmed Inc (NASDAQ: PAVM) jumps to multi-year highs. Co today announced that its majority-owned subsidiary Lucid Diagnostics filed a registration statement relating to a proposed initial public offering. PAVmed Inc. operates as a medical device company in the United States. The company’s lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett’s Esophagus (BE).
Veritone Inc (NASDAQ: VERI) announced an exclusive three-year international content licensing agreement with CBS News. The CBS News content collection can be found on co’s Veritone Licensing portal. Spikes to its highest levels since April. Veritone, Inc., together with its subsidiaries, provides artificial intelligence (AI) computing solutions in the United States and the United Kingdom. The company develops and operates aiWARE platform, an AI operating system that uses machine learning algorithms or AI models, such as cognitive queries, predictions, correlations, and analyses in real-time using AI models in various categories comprising transcription, face recognition, and object recognition to reveal valuable insights from vast amounts of structured and unstructured data. It also provides media advertising agency services, including media planning and strategy.
